Literature DB >> 19483729

Pim-1 plays a pivotal role in hypoxia-induced chemoresistance.

J Chen1, M Kobayashi, S Darmanin, Y Qiao, C Gully, R Zhao, S C Yeung, M H Lee.   

Abstract

Hypoxia changes the responses of cancer cells to many chemotherapy agents, resulting in chemoresistance. The underlying molecular mechanism of hypoxia-induced drug resistance remains unclear. Pim-1 is a survival kinase, which phosphorylates Bad at serine 112 to antagonize drug-induced apoptosis. Here we show that hypoxia increases Pim-1 in a hypoxia-inducible factor-1alpha-independent manner. Inhibition of Pim-1 function by dominant-negative Pim-1 dramatically restores the drug sensitivity to apoptosis induced by chemotherapy under hypoxic conditions in both in vitro and in vivo tumor models. Introduction of siRNAs for Pim-1 also resensitizes cancer cells to chemotherapy drugs under hypoxic conditions, whereas forced overexpression of Pim-1 endows solid tumor cells with resistance to cisplatin, even under normoxia. Dominant-negative Pim-1 prevents a decrease in mitochondrial transmembrane potential in solid tumor cells, which is normally induced by cisplatin (CDDP), followed by the reduced activity of Caspase-3 and Caspase-9, indicating that Pim-1 participates in hypoxia-induced drug resistance through the stabilization of mitochondrial transmembrane potential. Our results demonstrate that Pim-1 is a pivotal regulator involved in hypoxia-induced chemoresistance. Targeting Pim-1 may improve the chemotherapeutic strategy for solid tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19483729      PMCID: PMC3358117          DOI: 10.1038/onc.2009.124

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  37 in total

Review 1.  Perspectives on oxygen sensing.

Authors:  G L Semenza
Journal:  Cell       Date:  1999-08-06       Impact factor: 41.582

2.  The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway.

Authors:  M Lilly; J Sandholm; J J Cooper; P J Koskinen; A Kraft
Journal:  Oncogene       Date:  1999-07-08       Impact factor: 9.867

3.  Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements.

Authors:  P Vaupel; K Schlenger; C Knoop; M Höckel
Journal:  Cancer Res       Date:  1991-06-15       Impact factor: 12.701

4.  Enforced expression of the Mr 33,000 Pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells.

Authors:  M Lilly; A Kraft
Journal:  Cancer Res       Date:  1997-12-01       Impact factor: 12.701

5.  Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors.

Authors:  X Luo; I Budihardjo; H Zou; C Slaughter; X Wang
Journal:  Cell       Date:  1998-08-21       Impact factor: 41.582

6.  Hypoxia induces AP-1-regulated genes and AP-1 transcription factor binding in human endothelial and other cell types.

Authors:  R S Bandyopadhyay; M Phelan; D V Faller
Journal:  Biochim Biophys Acta       Date:  1995-10-17

Review 7.  Hypoxia and drug resistance.

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

8.  Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues.

Authors:  A C Koong; E Y Chen; A J Giaccia
Journal:  Cancer Res       Date:  1994-03-15       Impact factor: 12.701

9.  Study of cell kinetics in anaplastic thyroid carcinoma transplanted to nude mice.

Authors:  A Yoshida; M Fukazawa; H Ushio; Y Aiyoshi; S Soeda; K Ito
Journal:  J Surg Oncol       Date:  1989-05       Impact factor: 3.454

10.  Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death.

Authors:  N Zamzami; P Marchetti; M Castedo; D Decaudin; A Macho; T Hirsch; S A Susin; P X Petit; B Mignotte; G Kroemer
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

View more
  39 in total

Review 1.  For better or for worse: the role of Pim oncogenes in tumorigenesis.

Authors:  Martijn C Nawijn; Andrej Alendar; Anton Berns
Journal:  Nat Rev Cancer       Date:  2010-12-09       Impact factor: 60.716

2.  IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines.

Authors:  Katherine M Block; Neale T Hanke; Erin A Maine; Amanda F Baker
Journal:  Pancreas       Date:  2012-07       Impact factor: 3.327

3.  Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.

Authors:  Dapeng Xu; Michael G Cobb; Lily Gavilano; Sam M Witherspoon; Daniel Williams; Catherine D White; Pietro Taverna; Brian K Bednarski; Hong Jin Kim; Albert S Baldwin; Antonio T Baines
Journal:  Cancer Biol Ther       Date:  2013-06       Impact factor: 4.742

4.  Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors.

Authors:  Albert A Antolín; Jordi Mestres
Journal:  Oncotarget       Date:  2014-05-30

5.  The PI3K/Akt Pathway Regulates Oxygen Metabolism via Pyruvate Dehydrogenase (PDH)-E1α Phosphorylation.

Authors:  George J Cerniglia; Souvik Dey; Shannon M Gallagher-Colombo; Natalie A Daurio; Stephen Tuttle; Theresa M Busch; Alexander Lin; Ramon Sun; Tatiana V Esipova; Sergei A Vinogradov; Nicholas Denko; Constantinos Koumenis; Amit Maity
Journal:  Mol Cancer Ther       Date:  2015-05-20       Impact factor: 6.261

6.  Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma.

Authors:  Gunther Boysen; Damaris Bausch-Fluck; Claudio R Thoma; Anna M Nowicka; Daniel P Stiehl; Igor Cima; Van-Duc Luu; Adriana von Teichman; Thomas Hermanns; Tullio Sulser; Barbara Ingold-Heppner; Niklaus Fankhauser; Roland H Wenger; Wilhelm Krek; Peter Schraml; Bernd Wollscheid; Holger Moch
Journal:  Neoplasia       Date:  2012-06       Impact factor: 5.715

Review 7.  PIM kinase (and Akt) biology and signaling in tumors.

Authors:  Noel A Warfel; Andrew S Kraft
Journal:  Pharmacol Ther       Date:  2015-03-05       Impact factor: 12.310

Review 8.  PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.

Authors:  Laurent Brault; Christelle Gasser; Franz Bracher; Kilian Huber; Stefan Knapp; Jürg Schwaller
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

9.  The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.

Authors:  F F Blanco; M Jimbo; J Wulfkuhle; I Gallagher; J Deng; L Enyenihi; N Meisner-Kober; E Londin; I Rigoutsos; J A Sawicki; M V Risbud; A K Witkiewicz; P A McCue; W Jiang; H Rui; C J Yeo; E Petricoin; J M Winter; J R Brody
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

10.  PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.

Authors:  Noel A Warfel; Alva G Sainz; Jin H Song; Andrew S Kraft
Journal:  Mol Cancer Ther       Date:  2016-05-16       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.